A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT06637501 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Sonrotoclax
DRUG: Zanubrutinib

Sponsor

BeOne Medicines